|
IDS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.97022431492178E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.31050004181787E-09 |
| Normal-vs-Stage2 |
3.772000E-01 |
| Normal-vs-Stage3 |
2.99400000347561E-08 |
| Normal-vs-Stage4 |
1.20860000007994E-07 |
| Stage1-vs-Stage2 |
1.680050E-02 |
| Stage1-vs-Stage3 |
2.163600E-01 |
| Stage1-vs-Stage4 |
4.783700E-02 |
| Stage2-vs-Stage3 |
5.063700E-03 |
| Stage2-vs-Stage4 |
1.217370E-03 |
| Stage3-vs-Stage4 |
3.737200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.71525074330748E-14 |
| Normal-vs-AfricanAmerican |
1.878590E-03 |
| Normal-vs-Asian |
1.67293999999707E-05 |
| Caucasian-vs-AfricanAmerican |
7.743400E-01 |
| Caucasian-vs-Asian |
7.691200E-01 |
| AfricanAmerican-vs-Asian |
6.328000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.95211999999279E-05 |
| Normal-vs-Female |
3.24407167795471E-12 |
| Male-vs-Female |
1.594630E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.34209998670087E-09 |
| Normal-vs-Age(41-60Yrs) |
1.01310004829713E-09 |
| Normal-vs-Age(61-80Yrs) |
1.543570E-03 |
| Normal-vs-Age(81-100Yrs) |
1.606630E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.612400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.287630E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.872800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.807210E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.357000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.331400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.017800E-03 |
| Classical-VS-Follicular |
1.11022302462516E-16 |
| Classical-VS-Other |
3.958400E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.77524661637563E-13 |
| Tall-VS-Other |
4.279300E-03 |
| Tall-VS-Normal |
1.29549999616785E-08 |
| Follicular-VS-Other |
3.087800E-01 |
| Follicular-VS-Normal |
2.633800E-02 |
| Other-VS-Normal |
8.128400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.047200E-04 |
| Normal-vs-N1 |
6.17279999999276E-05 |
| N0-vs-N1 |
6.004500E-02 |
|
|
